Interesting Papers

Dose Findings

• Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs
• Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study
• DROID: dose-ranging approach to optimizing dose in oncology drug development

Clinical Trial

• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial (Antonia et al. (2016), link)

References

Antonia, Scott J, José A López-Martin, Johanna Bendell, Patrick A Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, et al. 2016. “Nivolumab Alone and Nivolumab Plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): A Multicentre, Open-Label, Phase 1/2 Trial.” The Lancet Oncology 17 (7): 883–95.